The premier partnering event in China
September 20–21, 2023 | Shanghai
September 25–26, 2023 | Virtual
ChinaBio® Partnering Forum Content
Prepare for your partnering experience with the most accurate and up-to-date information on China life sciences.
China Life Science is off to an Impressive Start in 2021
The China life science market's record-setting activity from 2020 continues in 2021. Read this infographic to review the impressive activity that took place in January and February, setting up the stage for another record year.
The infographic covers:
- Licensing and Partnering
State of China Life Science: 2021
Back on Track - VC, Partnering and IPOs Exploding
Download this exclusive report by ChinaBio® to review all of the financing and partnering trends in this vibrant sector.
- VC/PE Fundraising: $56.1 billion; 2.3 times 2019;
- VC/PE Investments: $28.5 billion; 2.0 times 2019;
- IPOs: $23.3 billion; 2.9 times 2019;
- Partnering: $30.5 billion; 1.7 times 2019
Johnson & Johnson Innovation Interview
In this exclusive interview with William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation and Dan Wang, MD, MBA, MPH, Head, Johnson & Johnson Innovation, Asia Pacific, we learn about their approach to partnering with stakeholders across the life science ecosystem, exciting collaborations with a global network of early-stage entrepreneurs, and opportunities to foster innovation and accelerate R&D.
Bigger deals, higher valuations, greater access to capital
The biopharma industry continues to fare well in the global capital markets, providing companies with opportunities to raise impressive funding rounds and launch impressive IPOs. Whether in Shanghai, New York or Hong Kong, the sector is hot with record-breaking IPOs, including two of the world’s largest. The CEOs of RemeGen, JW Therapeutics and I-Mab share their insights on navigating the road to success.
Looking ahead – what to expect in the new world order
Despite Covid-19’s devastating impact on lives and economies around the world, investments and deals in the biopharma sector were robust, especially in China. Companies seeking to launch or expand in China are strategically placing their bets to maximize growth opportunities. Executives from ChinaBio Group. Bayer Healthcare, Qiming Venture Partners, Decheng Capital and ATLATL Innovation Center share their forecasts for 2021.
Top Biotech Deals in China
Discover the deals transforming China biotech. More than $12 billion in biopharma financing, alliances, IPOs, and new funds have been generated so far this year in China. Learn the details of these deals when you read this new infographic.
J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.
Roche’s approach to drug discovery, innovation and meeting patients' needs
In an exclusive interview James Sabry, Global Head of Roche Pharma Partnering, discusses Roche’s approach to discovering scientific breakthroughs, accelerating innovative research, collaborating with stakeholders, and meeting unmet medical needs in China and around the world.
China's Challenges in the Wake of COVID-19
Gain a rare peek into the policies behind the vaccines race in China and the impact COVID-19 has had on its pharmaceutical supply chains, plus much more in this exclusive article pack from Pharma Intelligence.